Suvanza Pharma, LLC
Other OTCTotal Valuation
Suvanza Pharma, LLC carries a market capitalization of 1.01M, placing it among publicly traded companies globally. Its enterprise value stands at -379,000.00, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.01M |
| Enterprise Value | -379,000.00 |
Share Statistics
Suvanza Pharma, LLC currently has 109,269.00 shares outstanding.
| Shares Outstanding | 109,269.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 19.71M |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Suvanza Pharma, LLC maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.89 |
| Quick Ratio | 0.23 |
| Debt / Equity | 1.60 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -138.45 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Suvanza Pharma, LLC's stock has declined approximately -99.6% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.6% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Suvanza Pharma, LLC generated 7,000.00 in revenue and converted that into -15.41M in net income, yielding earnings per share of -146.89. EBITDA reached -11.14M, while operating income came in at -15.62M.
| Revenue | 7,000.00 |
| Gross Profit | N/A |
| Operating Income | -15.62M |
| Pretax Income | N/A |
| Net Income | -15.41M |
| EBITDA | -11.14M |
| EBIT | -15.62M |
| Earnings Per Share (EPS) | -146.89 |
Balance Sheet
Suvanza Pharma, LLC holds 446,000.00 in cash and equivalents against 67,000.00 in total debt, resulting in a net debt position of -446,000.00. Total book value stands at -7.93M, with working capital of -226,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 446,000.00 |
| Total Debt | 67,000.00 |
| Net Debt | -446,000.00 |
| Equity (Book Value) | -7.93M |
| Book Value Per Share | -75.58 |
| Working Capital | -226,000.00 |
Cash Flow
Suvanza Pharma, LLC produced -11.39M in operating cash flow over the past twelve months. After subtracting -314,000.00 in capital expenditures, free cash flow totaled -11.71M - equivalent to -111.58 per share.
| Operating Cash Flow | -11.39M |
| Capital Expenditures | -314,000.00 |
| Free Cash Flow | -11.71M |
| FCF Per Share | -111.58 |
Margins
Suvanza Pharma, LLC operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -223,171.43 and net profit margin of -220,142.86 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -223,171.43 |
| Pretax Margin | N/A |
| Profit Margin | -220,142.86 |
| EBITDA Margin | -159,214.29 |
Stock Splits
Suvanza Pharma, LLC's most recent stock split took place on September 10, 2010 with a 100:1 split ratio.
| Last Split Date | 9/10/2010 |
| Split Ratio | 100:1 |
Scores
Suvanza Pharma, LLC posts an Altman Z-Score of -24.09, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -24.09 |